Efficacy and Safety of the Treatment with Bone Marrow Mesenchymal Stem Cells of the Patients with Aplastic Anemia

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 5144-5144
Author(s):  
Yang Xiao ◽  
Yang Gao

Abstract Abstract 5144 Objective Summarizing the features of bone marrow mesenchymal stem cells, the pathogenesis of aplastic anemia, and the characteristics of bone marrow mesenchymal stem cells in patient affected by aplastic anemia;investigating the feasibility of implanting bone marrow mesenchymal stem cells for the treatment of aplastic anemia, providing a new mentality for the aplastic anemia's clinical treatment. Methods Search the documents utilized by the CNKI, CBM, PubMED and Highwire Press database. According to the retrieved result, a summary about the bone marrow mesenchymal stem cells characteristic and the feasibility of implanting bone marrow mesenchymal stem cells for the treatment of aplastic anemia was made. Results 1. The bone marrow mesenchymal stem cells(bone marrow mesenchymal stem cells, BMSC)is another important ingredient in the bone marrow, besides hematopoietic stem cells. It is easy to separate, raise, multiply and purify mesenchymal stem cells. It still carrys the qualities of stem cells after many generations of rising. When raised in vitro, BMSC may secrete many kinds of cell factors and the growth factors,and has the long-term hematopoietic supporting function, which does not only participate in the production hemopoiesis micro environment support hemopoiesis directly, but also able to grow and differentiate into various hematopoiesis supporting bone marrow matrix cells in the suitable condition. 2. BMSC has the great potential in self-renewal and multi-direction differentiation. Not only can it take function as substitute cells in the tissue framework, it also present good application prospect with regard to hematopoietic reconstruction, transplant immunity, and genetic treatment. 3. BMSC can repair the damage of hematopoietic micro environment(HME), and promote the reconstruction of hematopoiesis and immunity after transplant. 4. The low immunogenic and antigen present ability of BMSC provide the molecular foundation for the wide application of BMSC in stem cells transplant. 5. The pathogenesis of aplastic anemia(aplastic anemia, AA)is very complicated. The current belief is that aplastic anemia is related to the intrinsic multiplication flaw of hematopietic stem cells, the inadequate function of the hematopoietic micro environment, and the disorder of organism immune function. Studies have proved that there's the remarkable decrease of ectogenous hematopoietic supporting function and immuno-suppression capability of BMSC in aplastic anemia. Nowadays, methods have been established in separating, raising, and multiplying BMSC outside the human body. Besides, studies have revealed that transplanting BMSC can restore the hematopoietic micro environment, and the BMSC plays an important part in modulating transplant immunity. 6. Observe the efficacy and safety of the treatment on 11 patients of aplastic anemia with BMSC and the outcome indicate that the treatment is effective and safe. Accordingly, there's a good prospect for applying BMSC transplant as the treatment for aplastic anemia. Conclusions It has a good effect and prospect to apply bone mesenchymal stem cells transplant to the treatment of aplastic anemia. It provides a new approach to the clinical treatment of aplastic anemia. Disclosures: No relevant conflicts of interest to declare.

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Chandra Prakash Chaturvedi ◽  
Naresh Kumar Tripathy ◽  
Ekta Minocha ◽  
Akhilesh Sharma ◽  
Khaliqur Rahman ◽  
...  

We have investigated the expression of RNA transcripts of hematopoiesis regulatory molecules, viz., macrophage inflammatory protein (MIP)-1α, tumor necrosis factor (TNF)-α, granulocyte colony-stimulating factor (G-CSF), stromal cell-derived factor (SDF)-1α, stem cell factor (SCF), and transforming growth factor (TGF)-βin lipopolysaccharide-induced bone marrow mesenchymal stem cells (BM-MSCs) and levels of their soluble forms in the culture supernatants of BM-MSCs and BM plasma of patients with acquired aplastic anemia (AA) (n=29) and controls (n=29). The BM-MSCs of AA patients as compared to controls had markedly lower expression of MIP-1αtranscripts (p<0.001), higher expression of TNF-α(p<0.001), G-CSF (p<0.001), and SDF-1α(p<0.01) transcripts, and no difference in the expression of SCF and TGF-βtranscripts. The culture supernatants of BM-MSCs and BM plasma of AA patients in comparison to controls also had lower levels of MIP-1α(p<0.01andp<0.001, respectively) and higher levels of TNF-α(p<0.05for both) and G-CSF (p<0.05andp<0.001, respectively) but with no difference in the levels of SDF-1αand SCF. The levels of TGF-βwere although similar in culture supernatants of BM-MSCs of both the groups, but they were significantly lower in BM plasma of the patients than controls (p<0.001). Our data shows that BM-MSCs of AA patients have altered expression of hematopoiesis regulatory molecules suggesting that they may have a role in the pathogenesis of the disease.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2911-2911
Author(s):  
Lynne Margaret van Velzen-Ball ◽  
Katarina Le Blanc ◽  
Arjen C. Lankester ◽  
Helene Roelofs ◽  
Maarten Egeler ◽  
...  

Abstract Graft failure or rejection is an identified problem in haplo-identical or second attempt transplantation. In the bone marrow, mesenchymal stem cells (MSCs) have been identified and shown in animal models to enhance hematopoietic stem cell (HSC) engraftment. Advances in techniques and higher quality culture components have allowed the development of an MSC expansion procedure resulting in sufficient MSCs for clinical application. Adult studies have suggested that co-transplantation of MSCs and HSCs in the HLA-identical setting, is feasible and safe. Here we present the first combined clinical experience within the EBMT MSC expansion consortium with respect to co-transplantation of haplo-identical MSCs in the pediatric allogeneic transplantation setting. Six weeks before the SCT, 50 cc of bone marrow are sampled under sterile conditions. Density gradient-separated MNCs are plated into tissue culture flasks in low-glucose DMEM supplemented with 10% fetal calf serum and incubated at 370C with 5% CO2. At 70% confluence, the cells are trypsinized and re-plated at 4x103 cells/ cm2 until the target dose of 1–2 x106/kg recipient body weight is obtained. Enrichment and expansion of MSCs is performed under GMP conditions in nationally accredited laboratories. MSCs (either fresh or cryopreserved) are administered i.v. 4 hours before infusion of donor HSCs. To date 4 children have undergone co-transplantation. Patient characteristics are summarized in the table. All toxicities associated with the procedure were documented, as were the engraftment kinetics and immune recovery. The study was carried out with approval of the respective local ethical committees. The data indicate that expansion and co-transplantation of MSCs is feasible and well tolerated. While the study is ongoing initial engraftment and immune recovery data (compared to historical data) is encouraging and to date there have been no episodes of graft rejection or severe adverse events related to this treatment. Patient characteristics Patient demographics HSC characteristics MSC characteristics UPN Gender Age Diagnosis Donor CD34 dose (106/kg) Donor Cell dose (106/kg) 1 M 15 ANLL mother-haplo 16 mother 1.5 2 M 2 XLPD father-haplo 20 father 1.9 3 M 2 XLPD father-haplo 18.7 father 1.56 4 M 8 SAA URD (2 loci mismatched) 2.65 mother 1.0


2021 ◽  
Vol 12 (4) ◽  
Author(s):  
Han-zhou Qi ◽  
Yi-ling Ye ◽  
Yuan Suo ◽  
Hong Qu ◽  
Hai-yan Zhang ◽  
...  

AbstractChronic graft-versus-host disease (cGVHD) is the main cause of non-relapse mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Mesenchymal stem cells (MSCs) in bone marrow (BM) remain unclear in the pathophysiology of cGVHD. In this study, we analyzed BM-MSCs from 66 patients after allo-HSCT, including 33 with active cGVHD and 33 without cGVHD. BM-MSCs showed similar morphology, frequency, phenotype, and proliferation in patients with or without cGVHD. MSCs from the active cGVHD group showed a decreased apoptosis rate (P < 0.01). Osteogenic capacity was increased while adipogenic capacity was decreased in the active cGVHD MSCs compared with no-cGVHD MSCs. The expressions of osteogenic gene RUNX2 and COL1A1 were higher (P < 0.001) while adipogenic gene PPAR-γ and FABP4 were lower (P < 0.001) in the active cGVHD MSCs than no-cGVHD MSCs. These changes were associated with the severity of cGVHD (P < 0.0001; r = 0.534, r = 0.476, r = −0.796, and r = −0.747, respectively in RUNX2, COL1A1, PPAR-γ, and FABP4). The expression of Wnt/β-catenin pathway ligand Wnt3a was increased in cGVHD-MSCs. The dysfunction of cGVHD-MSCs could be reversed by Dickkopf related protein 1(DKK1) to inhibit the binding of Wnt3a. In summary, the differentiation of BM-MSCs was abnormal in active cGVHD, and its underlying mechanism is the upregulated of Wnt3a through Wnt/β-catenin signaling pathway of MSCs.


Sign in / Sign up

Export Citation Format

Share Document